Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,015 shares of the biopharmaceutical company’s stock after selling 1,128 shares during the quarter. Cresset Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,583,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. Activest Wealth Management boosted its stake in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the period. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $27,000. Colonial Trust Advisors acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. SouthState Corp boosted its position in shares of Regeneron Pharmaceuticals by 550.0% during the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 44 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $31,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $692.58 on Wednesday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The firm’s fifty day simple moving average is $656.15 and its 200-day simple moving average is $589.72. The firm has a market capitalization of $72.79 billion, a price-to-earnings ratio of 16.58, a PEG ratio of 2.01 and a beta of 0.37. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $791.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the firm earned $12.46 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on REGN. Canaccord Genuity Group upped their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Sanford C. Bernstein lifted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $777.36.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.